Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Published:2023-01 Issue:1 Volume:164 Page:72-88.e18
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Haber Philipp K.,Castet Florian,Torres-Martin Miguel,Andreu-Oller Carmen,Puigvehí Marc,Miho Maeda,Radu Pompilia,Dufour Jean-Francois,Verslype Chris,Zimpel Carolin,Marquardt Jens U.,Galle Peter R.,Vogel Arndt,Bathon Melanie,Meyer Tim,Labgaa Ismail,Digklia Antonia,Roberts Lewis R.,Mohamed Ali Mohamed A.,Mínguez Beatriz,Citterio Davide,Mazzaferro Vincenzo,Finkelmeier Fabian,Trojan Jörg,Özdirik Burcin,Müller Tobias,Schmelzle Moritz,Bejjani Anthony,Sung Max W.,Schwartz Myron E.,Finn Richard S.,Thung Swan,Villanueva Augusto,Sia Daniela,Llovet Josep M.^ORCID

Funder

Bayer HealthCare Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference65 articles.

1. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021

2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

4. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC);Finn;J Clin Oncol,2021

5. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1;International Immunopharmacology;2024-12

2. Immunotherapy for hepatocellular carcinoma;JHEP Reports;2024-10

3. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

4. Specific features of ß-catenin-mutated hepatocellular carcinomas;British Journal of Cancer;2024-09-11

5. Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era;Expert Review of Molecular Diagnostics;2024-08-28